PureTech Health plc (NASDAQ:PRTC – Free Report) – Analysts at Leerink Partnrs cut their FY2024 earnings estimates for PureTech Health in a note issued to investors on Wednesday, August 28th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($3.06) per share for the year, down from their previous forecast of ($2.73). The consensus estimate for PureTech Health’s current full-year earnings is ($3.90) per share. Leerink Partnrs also issued estimates for PureTech Health’s FY2025 earnings at ($2.75) EPS, FY2026 earnings at ($5.59) EPS, FY2027 earnings at ($0.65) EPS and FY2028 earnings at $4.08 EPS.
PureTech Health Trading Down 6.7 %
Shares of PureTech Health stock opened at $21.45 on Monday. PureTech Health has a 52-week low of $17.08 and a 52-week high of $34.00. The company has a 50 day moving average of $22.65 and a 200 day moving average of $25.85.
Hedge Funds Weigh In On PureTech Health
PureTech Health Company Profile
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Read More
- Five stocks we like better than PureTech Health
- 5 discounted opportunities for dividend growth investors
- 3 Small Cap Stocks That Insiders Are Buying
- What are earnings reports?
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- Most Volatile Stocks, What Investors Need to Know
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.